MedTrace Logo

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

NCT07247383 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-11-25

No results posted yet for this study

Summary

This is a phase II, prospective clinical study to evaluate the efficacy and safety of Orelabrutinib combined with Low-Dose Radiotherapy or Rituximab in the treatment of Ocular Adnexal MALT Lymphoma

Conditions

  • Marginal Zone Lymphoma of Ocular Adnexal
  • Marginal Zone Lymphoma(MZL)

Interventions

DRUG

Orelabrutinib (ICP-022)

Orelabrutinib was administered in 4 or 6 cycles, respectively, based on subjects' AnnArbor stage as assessed by PETCT，150mg QD D1-28

RADIATION

radiotherapy

Radiotherapy 2Gy\*2

DRUG

Rituximab (R)

Rituximab 375mg/m2 D1

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-19
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07247383 on ClinicalTrials.gov